William Blair Maintains Their Hold Rating on Amgen Inc (AMGN)


William Blair analyst Matt Phipps maintained a Hold rating on Amgen Inc (AMGN) on September 9. The company’s shares closed last Monday at $194.

According to TipRanks.com, Phipps is ranked 0 out of 5 stars with an average return of -14.9% and a 39.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Autolus Therapeutics Plc, and Kezar Life Sciences Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen Inc with a $215.50 average price target, implying a 9.9% upside from current levels. In a report issued on August 26, J.P. Morgan also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Amgen Inc’s market cap is currently $116.3B and has a P/E ratio of 15.36. The company has a Price to Book ratio of 10.82.

Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMGN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts